New medicines for malaria

作者: Benjamin Mordmüller

DOI: 10.1007/S00508-010-1330-4

关键词:

摘要: Development of new medicines for malaria is a challenging and important topic applied research because malarial parasites rapidly adapt to man-made interventions. Best studied examples are widely used drugs such as chloroquine, sulfadoxin-pyrimethamine (SP), and, recently, artemisinins; all them can lose efficacy after large-scale introduction. In addition drugs, vaccines re-emerged on the agenda funding bodies institutions period quietness desperation. This time communities' aims high: registered effective malaria-vaccine. So far, only one candidate shows modest [1], quantum leap in vaccine research, whereas others have not met high expectations [2–4]. this overview, I will summarize basic thoughts principles behind our work illustrate with current projects my group.

参考文章(30)
C Oeuvray, H Bouharoun-Tayoun, H Gras-Masse, E Bottius, T Kaidoh, M Aikawa, MC Filgueira, A Tartar, P Druilhe, Merozoite surface protein-3: a malaria protein inducing antibodies that promote Plasmodium falciparum killing by cooperation with blood monocytes Blood. ,vol. 84, pp. 1594- 1602 ,(1994) , 10.1182/BLOOD.V84.5.1594.1594
S. COHEN, I. A. McGREGOR, S. CARRINGTON, Gamma-Globulin and Acquired Immunity to Human Malaria Nature. ,vol. 192, pp. 733- 737 ,(1961) , 10.1038/192733A0
Livia Vivas, Lauren Rattray, Lindsay Stewart, Emily Bongard, Brian L. Robinson, Wallace Peters, Simon L. Croft, Anti-malarial efficacy of pyronaridine and artesunate in combination in vitro and in vivo. Acta Tropica. ,vol. 105, pp. 222- 228 ,(2008) , 10.1016/J.ACTATROPICA.2007.12.005
Blaise Genton, Fadwa Al-Yaman, Inoni Betuela, Robin F Anders, Allan Saul, Kay Baea, Mata Mellombo, Jack Taraika, Graham V Brown, David Pye, David O Irving, Ingrid Felger, Hans-Peter Beck, Thomas A Smith, Michael P Alpers, Safety and immunogenicity of a three-component blood-stage malaria vaccine (MSP1, MSP2, RESA) against Plasmodium falciparum in Papua New Guinean children Vaccine. ,vol. 22, pp. 30- 41 ,(2003) , 10.1016/S0264-410X(03)00536-X
Christophe Biot, Guillaume Glorian, Lucien A. Maciejewski, Jacques S. Brocard, Olivier Domarle, Georgette Blampain, Pascal Millet, Alain J. Georges, Huguette Abessolo, Daniel Dive, Jacques Lebibi, Synthesis and antimalarial activity in vitro and in vivo of a new ferrocene-chloroquine analogue. Journal of Medicinal Chemistry. ,vol. 40, pp. 3715- 3718 ,(1997) , 10.1021/JM970401Y
F. Cosledan, L. Fraisse, A. Pellet, F. Guillou, B. Mordmuller, P. G. Kremsner, A. Moreno, D. Mazier, J.-P. Maffrand, B. Meunier, Selection of a trioxaquine as an antimalarial drug candidate Proceedings of the National Academy of Sciences of the United States of America. ,vol. 105, pp. 17579- 17584 ,(2008) , 10.1073/PNAS.0804338105
Bernhards R. Ogutu, Odika J. Apollo, Denise McKinney, Willis Okoth, Joram Siangla, Filip Dubovsky, Kathryn Tucker, John N. Waitumbi, Carter Diggs, Janet Wittes, Elissa Malkin, Amanda Leach, Lorraine A. Soisson, Jessica B. Milman, Lucas Otieno, Carolyn A. Holland, Mark Polhemus, Shon A. Remich, Christian F. Ockenhouse, Joe Cohen, W. Ripley Ballou, Samuel K. Martin, Evelina Angov, V. Ann Stewart, Jeffrey A. Lyon, D. Gray Heppner, Mark R. Withers, , Blood stage malaria vaccine eliciting high antigen-specific antibody concentrations confers no protection to young children in Western Kenya. PLOS ONE. ,vol. 4, pp. 1- 11 ,(2009) , 10.1371/JOURNAL.PONE.0004708
Meral Esen, Peter G. Kremsner, Regina Schleucher, Michael Gässler, Egeruan Babatunde Imoukhuede, Nathalie Imbault, Odile Leroy, Søren Jepsen, Birgitte Walther Knudsen, Michael Schumm, Jürgen Knobloch, Michael Theisen, Benjamin Mordmüller, Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate. Vaccine. ,vol. 27, pp. 6862- 6868 ,(2009) , 10.1016/J.VACCINE.2009.09.011
Benjamin Mordmuller, Peter Kremsner, Malarial parasites vs. antimalarials: never-ending rumble in the jungle. Current Molecular Medicine. ,vol. 6, pp. 247- 251 ,(2006) , 10.2174/156652406776055122